[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity]
| Autor: | A S, Sivkov, S V, Paukov, Iu V, Ruvinov, I V, Kukes |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Clinical Trials as Topic
Ticlopidine Drug-Related Side Effects and Adverse Reactions Myocardial Ischemia Clopidogrel Heptanoic Acids Enzyme Induction Atorvastatin Cytochrome P-450 CYP3A Cytochrome P-450 CYP3A Inhibitors Humans Drug Interactions Pharmacokinetics Pyrroles Hydroxymethylglutaryl-CoA Reductase Inhibitors Precision Medicine Platelet Aggregation Inhibitors |
| Zdroj: | Klinicheskaia meditsina. 88(2) |
| ISSN: | 0023-2149 |
| Popis: | Modern methods for the evaluation of drug interaction at the level of biotransformation system are discussed with special reference to the lidocaine test (MEGX) and measurement of cytochrome P-450 activity in patients with drug-induced oxidative processes in the liver. Interaction of atorvastatin with clopidogrel are shown to slightly reduce the desaggregative effect of the latter. It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|